Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Phase 1 Study of ADVM-022 (AAV.7m8-aflibercept) in Neovascular (Wet) Age-Related Macular Degeneration

Trial Profile

An Open Label Phase 1 Study of ADVM-022 (AAV.7m8-aflibercept) in Neovascular (Wet) Age-Related Macular Degeneration

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ADVM-022 (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions
  • Acronyms OPTIC
  • Sponsors Adverum Biotechnologies
  • Most Recent Events

    • 12 Mar 2020 According to an Adverum Biotechnologies media release, the company expects to present new data from this study in May 2020.
    • 12 Mar 2020 According to an Adverum Biotechnologies media release, patient dosing in cohort 3 is completed and patients are being screened in cohort 4.
    • 11 Mar 2020 According to an Adverum Biotechnologies media release, data will be presented at the companys gene therapy programs to be presented at the Association for Vision and Ophthalmology (ARVO) 2020 Congress in Baltimore, MD.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AskTheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top